FindTrial
Sign In

CYP2C19 genotyping

GENETIC4 trials

Sponsors

Vera HM Deneer, University of Pennsylvania, University of Florida, University of Southern California

Conditions

Acute Coronary SyndromeAcute Coronary Syndrome (ACS)Cardiovascular DiseasesGastroesophageal Reflux DiseaseMyocardial InfarctionNSTEMI - Non-ST Segment Elevation MISTEMISTEMI - ST Elevation Myocardial Infarction (MI)

Phase 4

Cost-effectiveness of Genotype Guided Treatment With Antiplatelet Drugs in STEMI Patients: Optimization of Treatment (POPular Genetics)
CompletedNCT01761786
Vera HM DeneerMyocardial Infarction, STEMI
Start: 2011-06-30End: 2019-04-04Updated: 2019-05-10
Implementing Precision Medicine Approaches to Guide Anti-platelet Selection
NCT04090281
University of Southern CaliforniaAcute Coronary Syndrome (ACS), NSTEMI - Non-ST Segment Elevation MI, STEMI - ST Elevation Myocardial Infarction (MI) +1
Start: 2020-03-13End: 2023-11-30Target: 200Updated: 2021-09-28

Unknown Phase

Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention
CompletedNCT02508116
University of PennsylvaniaAcute Coronary Syndrome, Cardiovascular Diseases
Start: 2014-11-30End: 2017-08-31Updated: 2018-11-07
Genotype-supported Versus Conventional Proton Pump Inhibitor Dosing
CompletedNCT02930824
University of FloridaGastroesophageal Reflux Disease
Start: 2016-12-31End: 2019-07-17Updated: 2024-05-16

Related Papers

Effects of CYP3A4*22 and CYP3A5 on clinical outcome in patients treated with ticagrelor for ST-segment elevation myocardial infarction: POPular Genetics sub-study
Frontiers in Pharmacology2022-12-053 citations
Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial
American Journal of Cardiovascular Drugs2021-09-0727 citations
Factor V Leiden Does Not Modify the Phenotype of Acute Coronary Syndrome or the Extent of Myocardial Necrosis
Journal of the American Heart Association2021-05-176 citations
Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype
Circulation Cardiovascular Interventions2021-03-1626 citations
Prospective <i>CYP2C19</i> Genotyping to Guide Antiplatelet Therapy Following Percutaneous Coronary Intervention
Circulation Genomic and Precision Medicine2020-02-0156 citations
A Genotype-Guided Strategy for Oral P2Y <sub>12</sub> Inhibitors in Primary PCI
New England Journal of Medicine2019-09-03597 citations
Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention.
2018-04-1147 citations
Sunday, 31 August 2014
European Heart Journal2014-09-0210 citations
CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study.
2014-03-2157 citations